1.1834
1.25%
-0.0166
Spero Therapeutics Inc stock is traded at $1.1834, with a volume of 53,039.
It is down -1.25% in the last 24 hours and down -7.42% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$1.20
Open:
$1.19
24h Volume:
53,039
Relative Volume:
0.23
Market Cap:
$62.16M
Revenue:
$76.19M
Net Income/Loss:
$-1.61M
P/E Ratio:
-4.5515
EPS:
-0.26
Net Cash Flow:
$28.98M
1W Performance:
-5.20%
1M Performance:
-7.42%
6M Performance:
-21.52%
1Y Performance:
-2.07%
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
SPRO | 1.185 | 62.16M | 76.19M | -1.61M | 28.98M | -0.26 |
VRTX | 447.30 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 745.59 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 592.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.57 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 104.51 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
Dec-16-20 | Initiated | Berenberg | Buy |
Sep-29-20 | Initiated | Evercore ISI | Outperform |
Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
Sep-09-19 | Initiated | Janney | Buy |
Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
Nov-27-17 | Initiated | BofA/Merrill | Neutral |
Nov-27-17 | Initiated | Oppenheimer | Outperform |
Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
TD Cowen Reaffirms “Hold” Rating for Spero Therapeutics (NASDAQ:SPRO) - Defense World
Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Spero Therapeutics (NASDAQ:SPRO) Receives Hold Rating from TD Cowen - MarketBeat
TD Cowen Downgrades Spero Therapeutics (SPRO) - MSN
Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Spero Therapeutics (NASDAQ:SPRO) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat
Spero Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Spero Therapeutics Inc. (SPRO) Quarterly 10-Q Report - Quartzy
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics Reports Wider Q3 Loss, Revenue Falls 47% Amid Restructuring | SPRO Stock News - StockTitan
What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnin - GuruFocus.com
What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings - Yahoo Finance
Spero Therapeutics (SPRO) Scheduled to Post Earnings on Thursday - Defense World
Spero Therapeutics (SPRO) to Release Earnings on Thursday - MarketBeat
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 - The Manila Times
Spero Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
HC Wainwright Expects Higher Earnings for Spero Therapeutics - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Spero shares hold Buy rating with target lowered on SPR720 Phase 2a results - Investing.com UK
HC Wainwright Cuts Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00 - MarketBeat
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding - Simply Wall St
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Cambridge biotech pulls plug on lung disease drug, cuts 39% of workforce - The Business Journals
Spero Therapeutics to lay off 39% of employees - PharmaLive
Spero Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com South Africa
Spero Therapeutics to Lay Off 39% of Employees - BioSpace
Spero Therapeutics stock hits 52-week low at $1.03 - Investing.com
Spero’s stock slides after antibiotic flops in Phase II trial - Yahoo Finance
Spero Therapeutics reports setback in SPR720 study By Investing.com - Investing.com South Africa
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies - Law360
Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program - MarketWatch
Spero to cut 39% of workforce on failed study, stock plunges 20% (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics reports setback in SPR720 study - Investing.com India
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics Dodges Investor Suit Over FDA Approval (1) - Bloomberg Law
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 - The Manila Times
Spero Therapeutics Announces Presentation of SPR719 (Active - GlobeNewswire
Spero Therapeutics reports promising in vitro NTM treatment data - Investing.com
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Market Insight: Spero Therapeutics Inc (SPRO)’s Notable Drop, Closing at 1.24 - The Dwinnex
An Analysis of Spero Therapeutics Inc (SPRO)’s Potential Price Growth - Knox Daily
Spero Therapeutics' (SPRO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Spero Therapeutics reports promising Phase 1 trial results for NTM-PD drug - Investing.com
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy - ForexTV.com
Spero Therapeutics Announces Publication of SPR720 Phase 1 - GlobeNewswire
Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below 200-Day Moving Average of $1.46 - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200-Day Moving Average of $1.48 - MarketBeat
Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsight - PR Newswire UK
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):